Melatonin May Be Served As A Potential Anti-Fibrotic Drug

In Liver Cirrhosis Melatonin May Be Served As A Potential Anti-Fibrotic Drug
Main Category: Liver Disease / Hepatitis
Also Included In: Biology / Biochemistry
Article Date: 01 Apr 2009 - 2:00 PDT

In China, the incidence of liver cirrhosis is still high. Liver cirrhosis results from fibrosis. If treated properly at fibrosis stage, cirrhosis can be prevented. However, no effective antifibrosis drugs are available at present. Several lines of evidences suggest that oxidative stress plays an important role in the etiopathogenesis of hepatic fibrosis. Melatonin can protect cells, tissues, and organs against oxidative damage induced by a variety of free-radical-generating agents and processes.

A research team led by Professor Jian-Ming Xu from the First Affiliated Hospital of Anhui Medical University, China evaluated the possible fibrosuppressant effect of melatonin in rat. Their study was published on March 28, 2009 in the World Journal of Gastroenterology.

In this study, hepatic fibrosis in rats was successfully induced by subcutaneous injection of sterile CCl4 twice weekly for a total of 12 wk. At the beginning of injection of CCl4, melatonin (2.5, 5, 10 mg/kg body weight) was intraperitoneally administered to the rats daily for 12 wk. Hepatic fibrotic changes were evaluated biochemically by measuring tissue hydroxyproline levels and histopathogical examination. The serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST) were used to evaluate the hepatic injury. Hepatic oxidative stress markers were evaluated by changes in the amount of lipid peroxides, measured as malondialdehyde (MDA) and glutathione peroxidase (GPx) in liver homogenates. Serum hyaluronic acid (HA), laminin (LN), and procollagen 3 N-terminal peptide (P3NP) were determined as serum markers of hepatic fibrogenesis.

Their results suggested that treatment with melatonin (10 mg/kg) could decrease the scores of hepatic fibrosis grading, reduced the contents of HA, LN in serum and Hydroxyproline (HYP) in liver, treatment with melatonin (5,10 mg/kg ) could decrease serum levels of ALT, AST and blocked the increase in MDA in rats with hepatic injury caused by CCl4.

Their result indicated melatonin could ameliorate CCl4-induced hepatic fibrosis in rats. The protective effect of melatonin on hepatic fibrosis may be related to its antioxidant activities. This may provide a basis for further studies on the potentially protective effect of melatonin on liver function in cirrhotic patients

Notes:

Reference: Hong RT, Xu JM, Mei Q. Melatonin ameliorates experimental hepatic fibrosis induced by carbon tetrachloride in rats. World J Gastroenterol 2009; 15(12): 1452-1458 http://www.wjgnet.com/1007-9327/15/1452.asp

Correspondence to: Jian-Ming Xu, Professor, Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China.

[evangelin]

Thanks.  I've been giving it to Joe to keep his platelets up but it is nice to hope it may be helping in other ways also.
Ev

[GoofyDad]

This has come up before - possibly earlier results from the same study. Note the dosage of 10mg/KG. That's many times the normal human dosing - and at 5mg/KG (still many times) they apparently didn't get the results.

http://insomnia.emedtv.com/melatonin/melatonin-dosage.html

[evangelin]

There are quite a few  possible drug interactions with melatonin listed at the site GoofyDad posted.  You better check it out before taking it.  I'm glad I haven't killed Joe yet with supplements.  I'm going to proceed giving him 3 mg. a night for now.  Platelets aren't a big concern now that he is off Tx.
Ev